SUSMED,Inc.
TTSE:4263354.00
JPY
-10.00
(-2.75%)
ISIN
JP3319150003
Return %
Stock
S&P 500
1Y
-62.34
14.20
3Y
-75.90
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Taro Ueno
- Full Time Employees
- 50
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nihombashi Honcho M-SQUARE Tokyo TY Japan 103-0023
- IPO Date
- Dec 24, 2021
- Website
- susmed.co.jp
- Similar Companies
- Business
- SUSMED, Inc. (4263.T) develops and provides sustainable medical and healthcare solutions focused on reducing environmental impact in the medical field. The company offers products including eco-friendly disposable medical supplies such as paper-based gowns, drapes, and trays; reusable sterilization containers and related accessories; and consulting services for hospital waste reduction and sustainability initiatives. SUSMED operates primarily in Japan, serving hospitals, clinics, and medical facilities with a focus on the domestic healthcare sector. Founded in 2022 and headquartered in Tokyo, Japan, SUSMED emphasizes circular economy principles in medical waste management, targeting large-scale healthcare providers seeking compliance with environmental regulations and cost efficiencies. Its product lineup features proprietary brands like the "Green Series" for single-use paper medical wearables and the "Cycle Container" system for durable sterilization and transport, complemented by digital tools for tracking waste metrics. In recent developments, SUSMED expanded its operations through a strategic partnership with major Japanese hospital chains in 2024 to pilot zero-waste programs, alongside securing a JPY 1.2 billion funding round led by healthcare-focused venture capital firms to accelerate production scaling. The company launched its next-generation biodegradable infusion sets in early 2025, marking entry into fluid management products, and reorganized its business units to include an international division targeting Southeast Asian markets. These changes position SUSMED for growth amid rising demand for ESG-compliant medical supplies in Asia.